Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Current Alzheimer Research

• Publication date

  2007-08-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/156720507783018343PMID 18220522
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overview of protein aggregation in single, double, and triple neurodegenerative brain amyloidoses

  2007cited by this paper
• Oxidative stress induces nuclear translocation of C-terminus of alpha-synuclein in dopaminergic cells.

  2006cited by this paper
• Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.

  2006cited by this paper
• Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype.

  2006cited by this paper
• Interface between tauopathies and synucleinopathies: A tale of two proteins

  2006cited by this paper
• Relation of quantitative indexes of concurrent alpha-synuclein abnormalities to clinical outcome in autopsy-proven Alzheimer disease.

  2006cited by this paper
• Dequalinium-induced protofibril formation of alpha-synuclein.

  2006cited by this paper
• The alpha-synuclein mutation E46K promotes aggregation in cultured cells.

  2006cited by this paper
• Alpha-synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson's disease.

  2006cited by this paper
• Endogenous α-Synuclein Is Induced by Valproic Acid through Histone Deacetylase Inhibition and Participates in Neuroprotection against Glutamate-Induced Excitotoxicity

  2006cited by this paper
• Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry.

  2006cited by this paper
• The 11-mer repeats of human alpha-synuclein in vesicle interactions and lipid composition discrimination: a cooperative role.

  2006cited by this paper
• Tau‐predominant–associated pathology in a sporadic late‐onset Hallervorden–Spatz syndrome

  2006cited by this paper
• Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection.

  2006cited by this paper
• Pathophysiology of synuclein aggregation in Lewy body disease.

  2006cited by this paper
• Impairment of redox state and dopamine level induced by alpha-synuclein aggregation and the prevention effect of hsp70.

  2005cited by this paper
• Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation.

  2005cited by this paper
• Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.

  2005cited by this paper
• Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells.

  2005cited by this paper
• Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein.

  2005cited by this paper
• Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease.

  2005cited by this paper
• Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration.

  2005cited by this paper
• Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease.

  2005cited by this paper
• Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity.

  2005cited by this paper
• Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

  2005cited by this paper
• Dopamine promotes α‐synuclein aggregation into SDS‐resistant soluble oligomers via a distinct folding pathway

  2005cited by this paper
• Reversible Inhibition of α-Synuclein Fibrillization by Dopaminochrome-mediated Conformational Alterations*

  2005cited by this paper
• Heat Shock Protein 70 Inhibits α-Synuclein Fibril Formation via Preferential Binding to Prefibrillar Species*

  2005cited by this paper
• Protective effect of TAT‐delivered α‐synuclein: relevance of the C‐terminal domain and involvement of HSP70

  2004cited by this paper
• Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions.

  2004cited by this paper
• Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease.

  2004cited by this paper
• Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?

  2004cited by this paper
• Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective.

  2004cited by this paper
• An antiaggregation gene therapy strategy for Lewy body disease utilizing β-synuclein lentivirus in a transgenic model

  2004cited by this paper
• Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.

  2004cited by this paper
• Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease.

  2004cited by this paper
• Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation.

  2004cited by this paper
• Alpha-synuclein and transgenic mouse models.

  2004cited by this paper
• Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.

  2004cited by this paper
• Beta-synuclein exhibits chaperone activity more efficiently than alpha-synuclein.

  2004cited by this paper
• Differential expression of α‐synuclein isoforms in dementia with Lewy bodies

  2004cited by this paper
• Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila.

  2003cited by this paper
• Localization of alpha-, beta-, and gamma-synuclein during neuronal development and alterations associated with the neuronal response to axonal trauma.

  2003cited by this paper
• Colocalization of Tau and Alpha‐Synuclein Epitopes in Lewy Bodies

  2003cited by this paper
• The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation.

  2003cited by this paper
• Role of alpha-synuclein carboxy-terminus on fibril formation in vitro.

  2003cited by this paper
• Alpha-synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease.

  2003cited by this paper
• A Protein-Chameleon: Conformational Plasticity of α-Synuclein, a Disordered Protein Involved in Neurodegenerative Disorders

  2003cited by this paper
• Part I: parkin-associated proteins and Parkinson's disease.

  2003cited by this paper
• α‐Synuclein regulates neuronal survival via Bcl‐2 family expression and PI3/Akt kinase pathway

  2002cited by this paper
• alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells.

  2002cited by this paper
• beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.

  2001cited by this paper
• beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor.

  2001cited by this paper
• Early formation of mature amyloid‐β protein deposits in a mutant APP transgenic model depends on levels of Aβ1–42

  2001cited by this paper
• Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease.

  2001cited by this paper
• Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation.

  2000cited by this paper
• Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease?

  2000cited by this paper
• Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.

  2000cited by this paper
• Mouse models of alpha-synucleinopathy and Lewy pathology.

  2000cited by this paper
• Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry

  2000cited by this paper
• alpha-Synuclein shares physical and functional homology with 14-3-3 proteins.

  1999cited by this paper
• Influence of BDNF and FCS on viability and programmed cell death (PCD) of developing cortical chicken neurons in vitro.

  1998cited by this paper
• Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes*

  1998cited by this paper
• Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons.

  1997cited by this paper

• Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

  2019cites this paper
• Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.

  2014cites this paper
• Stability of Clinical Etiologic Diagnosis in Dementia and Mild Cognitive Impairment

  2013cites this paper
• Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective?

  2012cites this paper
• Rifampicin reduces &agr;-synuclein in a transgenic mouse model of multiple system atrophy

  2008cites this paper
• The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies.

  2008cites this paper